Monica DI Tommaso1, Consuelo Rosa1, Luciana Caravatta2, Antonietta Augurio1, Valentina Borzillo3, Sara DI Santo1, Francesca Perrotti1, Maria Taraborrelli1, Roberta Cianci4, Paolo Innocenti5, Pierluigi DI Sebastiano6, Antonella Colasante7, Domenico Angelucci7, Massimo Basti8, Giulia Sindici9, Lorenzo Mazzola10, Giuseppe Pizzicannella11, Nicola DI Bartolomeo5, Michele Marchioni12, Marta DI Nicola12, Domenico Genovesi1. 1. Department of Radiation Oncology, SS. Annunziata Hospital, G. D'Annunzio University, Chieti, Italy. 2. Department of Radiation Oncology, SS. Annunziata Hospital, G. D'Annunzio University, Chieti, Italy lcaravatta@hotmail.com. 3. Department of Radiation Therapy, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy. 4. Department of Radiology, SS. Annunziata Hospital, G. D'Annunzio University, Chieti, Italy. 5. Division of Surgery, Villa Serena Clinic, Città S. Angelo, Italy. 6. Department of Medical and Oral Sciences and Biotechnologies, G. D'Annunzio University, Chieti, Italy. 7. Division of Pathology, SS. Annunziata Hospital, Chieti, Italy. 8. Division of Surgery III, Santo Spirito Hospital, Pescara, Italy. 9. Division of Pathology, Santo Spirito Hospital, Pescara, Italy. 10. Division of Surgery, Renzetti Hospital, Lanciano, Italy. 11. Division of Pathology, Villa Serena Clinic, Città S. Angelo, Italy. 12. Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, G. D'Annunzio University, Chieti, Italy.
Abstract
AIM: Pathological complete response (pCR) and clinical outcomes [overall survival (OS), disease-free survival (DFS), locoregional control (LC)] were evaluated in a single-institution experience of different schedules of neoadjuvant chemoradiotherapy (CRT) for patients with locally advanced rectal cancer (LARC). PATIENTS AND METHODS: Data for 322 patients with LARC were retrospectively analyzed. pCR was evaluated according to Mandard tumor regression grade (TRG). The Kaplan-Meier method was used to estimate OS, DFS and LC. RESULTS: Three hundred and three (94.1%) patients underwent surgery. pCR was observed in 81 patients (26.7%), with TRG1-2 rate of 41.8%. The 5- and 10-year OS, DFS and LC rates were 82.5%±2.5% and 65.5%±3.8%, 81.2%±2.4% and 79.3%±2.9%, 93.1%±1.7% and 90.5%±2.1%, respectively. CONCLUSION: Neoadjuvant CRT in LARC patients resulted in favorable long-term oncological outcomes, with a high pCR rate and acceptable toxicity. Copyright
AIM: Pathological complete response (pCR) and clinical outcomes [overall survival (OS), disease-free survival (DFS), locoregional control (LC)] were evaluated in a single-institution experience of different schedules of neoadjuvant chemoradiotherapy (CRT) for patients with locally advanced rectal cancer (LARC). PATIENTS AND METHODS: Data for 322 patients with LARC were retrospectively analyzed. pCR was evaluated according to Mandard tumor regression grade (TRG). The Kaplan-Meier method was used to estimate OS, DFS and LC. RESULTS: Three hundred and three (94.1%) patients underwent surgery. pCR was observed in 81 patients (26.7%), with TRG1-2 rate of 41.8%. The 5- and 10-year OS, DFS and LC rates were 82.5%±2.5% and 65.5%±3.8%, 81.2%±2.4% and 79.3%±2.9%, 93.1%±1.7% and 90.5%±2.1%, respectively. CONCLUSION: Neoadjuvant CRT in LARC patients resulted in favorable long-term oncological outcomes, with a high pCR rate and acceptable toxicity. Copyright
Authors: Sarah Roels; Wim Duthoy; Karin Haustermans; Freddy Penninckx; Vincent Vandecaveye; Tom Boterberg; Wilfried De Neve Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-05 Impact factor: 7.038
Authors: Claus Rödel; Ullrich Graeven; Rainer Fietkau; Werner Hohenberger; Torsten Hothorn; Dirk Arnold; Ralf-Dieter Hofheinz; Michael Ghadimi; Hendrik A Wolff; Marga Lang-Welzenbach; Hans-Rudolf Raab; Christian Wittekind; Philipp Ströbel; Ludger Staib; Martin Wilhelm; Gerhard G Grabenbauer; Hans Hoffmanns; Fritz Lindemann; Anke Schlenska-Lange; Gunnar Folprecht; Rolf Sauer; Torsten Liersch Journal: Lancet Oncol Date: 2015-07-15 Impact factor: 41.316
Authors: Carmen J Allegra; Greg Yothers; Michael J O'Connell; Robert W Beart; Timothy F Wozniak; Henry C Pitot; Anthony F Shields; Jerome C Landry; David P Ryan; Amit Arora; Lisa S Evans; Nathan Bahary; Gamini Soori; Janice F Eakle; John M Robertson; Dennis F Moore; Michael R Mullane; Benjamin T Marchello; Patrick J Ward; Saima Sharif; Mark S Roh; Norman Wolmark Journal: J Natl Cancer Inst Date: 2015-09-14 Impact factor: 13.506
Authors: Fabio Maria Vecchio; Vincenzo Valentini; Bruce D Minsky; Gilbert D A Padula; Ennapadam S Venkatraman; Mario Balducci; Francesco Miccichè; Riccardo Ricci; Alessio Giuseppe Morganti; Maria Antonietta Gambacorta; Francesca Maurizi; Claudio Coco Journal: Int J Radiat Oncol Biol Phys Date: 2005-07-01 Impact factor: 7.038
Authors: Sameer P Desai; Basil F El-Rayes; Edgar Ben-Josef; Joel K Greenson; James A Knol; Emina H Huang; Kent A Griffith; Philip A Philip; Cornelius J McGinn; Mark M Zalupski Journal: Am J Clin Oncol Date: 2007-08 Impact factor: 2.339
Authors: Fiona G M Taylor; Philip Quirke; Richard J Heald; Brendan J Moran; Lennart Blomqvist; Ian R Swift; David Sebag-Montefiore; Paris Tekkis; Gina Brown Journal: J Clin Oncol Date: 2013-11-25 Impact factor: 44.544
Authors: Maria Antonietta Gambacorta; Vincenzo Valentini; Claudio Coco; Alberto Manno; Giovanni B Doglietto; Carlo Ratto; Maurizio Cosimelli; Francesco Miccichè; Francesca Maurizi; Luca Tagliaferri; Giovanna Mantini; Mario Balducci; Giuseppe La Torre; Brunella Barbaro; Aurelio Picciocchi Journal: Tumori Date: 2007 Mar-Apr